ABOUT THE EVENT
Date: Thursday, October 29, 2026 9–10am PDT
Event Location: Virtual
Biologic therapeutics are increasingly complex, with variations in sequence, PTMs, assembly, conjugation, and molecular transformation in vivo. These features can influence candidate quality, function, developability, and the interpretation of exposure. Mass spectrometry (MS) provides the molecular specificity and scalable workflows needed to translate these complexities into evidence-based discovery decisions.
This webinar presents tiered, fit-for-purpose MS strategies across the drug discovery funnel, from rapid confirmation for candidate triage to risk-directed characterization of structural liabilities and deeper assessment of final leads. Through case studies spanning mAbs, bispecifics, and ADCs, you will discover how MS can guide lead advancement and development planning.
Join this webinar to explore how MS can:
Apply the right analytical depth at each stage, from rapid confirmation to risk-directed studies and mechanistic understanding
Confirm molecular identity and assembly for candidate triage using intact, reduced, deglycosylated, subunit, and HTP MS
Localize structural liabilities and relate them to stability and function through peptide mapping, native MS, and other risk-directed studies
Define and measure the right analytes to characterize exposure, molecular integrity, cargo retention, and catabolites in vivo
Speaker:
Lei Guo, Ph.D., Senior Director, CRO Services
